Bandingkan Harga & Kinerja Niramas Utama Tbk. (JELI) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Niramas Utama Tbk. dan Organon Pharma Indonesia Tbk.: Niramas Utama Tbk. diperdagangkan di Rp515 (kapitalisasi pasar 670,98 M, volume 24 jam 3,31 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Niramas Utama Tbk. jauh lebih besar — sekitar 6,4× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| JELI | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 670,98 M | 104,4 M |
Volume | 3,31 jt | — |
Lot | 33,07 rb | — |
Perputaran | 1,71 M | — |
Harga Rata-rata | 516,6 | — |
Nilai Transaksi | 1,71 M | — |
Harga Ekuilibrium Indikatif | 515 | — |
Volume Ekuilibrium Indikatif | 680 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Niramas Utama Tbk.
PT. Niramas Utama Tbk. (the Company) formerly PT Nata Sari Raya was established based on Notarial Deed No. 86 dated 22 November 1990, by Notary Samsul Hadi, S.H. The Company started its commercial operations in 1994. The parent entity and the ultimate parent entity of the Company are PT Niramas Utama International and PT Supra Sentral Investama
Selengkapnya di halaman JELI →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
